‘I didn’t want to be on medica...
Are standard Alzheimer's meds plateauing? Explore Integrative Alzheimer's Treatment in China. Top hospitals are combining neurology & multi-target TCM to safely combat cognitive decline.
As a medical concierge provider, MedBridgeNZ doesn't treat—we facilitate. We expertly manage your Medical Tourism China journey, connecting you to top specialists.
Read the evidence: https://zurl.co/OtbUb
#Neurology #Alzheimers #MedicalConcierge #MedBridgeNZ #MedicalTourismChina #ChinaMedicalTourism

Home > Blog > Advanced Therapies & TechnologyKey Takeaways • Limitations of Single-Target Drugs: Mainstream single-target Alzheimer's medications often face a 6 to 12-month "efficacy plateau" and present significant side effect profiles, including gastrointestinal issues and Amyloid-Related Imaging Abnormalities (ARIA). • Integrative Clinical Evidence: A meta-analysis of 23 randomized controlled trials involving 2,035 patients demonstrated that integrating multi-target plant-based compounds with
Clinical trial: Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, PK and PD of Antisense Oligonucleotide AMX0114 Administered to Adult Participants With Amyotrophic Lateral Sclerosis
Clinical trial: Evaluation of the Effects of Laughter Yoga on Pain Intensity, Stress, and Beta-endorphin Levels in Patients With Multiple Sclerosis
Clinical trial: Comparison of Frailty, Physical Fitness Parameters, and Irisin Levels Between Patients With Multiple Sclerosis and Healthy Volunteers
Clinical trial: An Open-Label Clinical Study to Evaluate the Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Clinical trial: Influance of Walking Fatigability on Spatiotemporal Gait Parameters and Risk of Falling in Patients With Multiple Scalerosis
Clinical trial: A Clinical Study on the Safety and Tolerability of Universal STAR-T Cell Injection in Patients With Multiple Sclerosis.
Clinical trial: The Effect of an Exercise Intervention on Serum Glial Fibrillary Acidic Protein (GFAP), Brain Volumetry and and Functional Outcomes in Patients With Multiple Sclerosis: A Randomized Controlled Trial